OR WAIT null SECS
- About Us
- Advertise
- Contact Us
- Editorial Info
- Editorial Contacts
- Editorial Advisory Board
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2024 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Novasep Invests €5.1 million in Le Mans Site to Further Expand its Production Capacity for HPAPIs
Novasep increases its production capacity for HPAPIs with an investment in its site in Le Mans, France.
Novasep announced on March 15, 2022 that it has invested €5.1million (USD 5.6 million) into expanding its production capacity for highly potent active pharmaceutical ingredients (HPAPIs) on its site in Le Mans, France. The investment will continue to strengthen Novasep’s position as a contract development and manufacturing organization (CDMO) in APIs for cancer treatment.
The investment includes the addition of a new chemical synthesis workshop for HPAPIs, which will be commissioned in late 2023 and add 10 full-time jobs. The new workshop will also reduce environmental impact due to its more efficient manufacturing processes.
The new investment will align with Novasep’s expansion in the market of antibody-drug conjugates (ADCs). ADC based drugs are being established as a cornerstone of cancer therapy, which Novasep’s Le Mans site will continue to explore.
“The production at Le Mans site offers unparalleled flexibility to produce ADC payloads at different scales and in complete safety,” explained Rachel De Luca, director of the Le Mans site, in a press release. “We are increasing our production capacity to support the development of tomorrow's cancer drugs with agility, while enhancing the robustness of the supply chain of the commercial products of our historical customers.”
Source: Novasep
